title: Prophylactic urethral stenting with Memokath®028SW in prostate cancer patients undergoing prostate125I seed implants: phase I/II study.
abstract: OBJECTIVE
  To study the feasibility/toxicity of urethral stenting with the Memokath®028SW stent in patients undergoing prostate implant (PI) for prostate adenocarcinoma.
  
  
  METHODS
  An Investigational Device Exemption from the Food and Drug Administration (FDA) and institutional review board (IRB) approval were obtained. Twenty patients enrolled. Baseline American Urological Association (AUA) score was obtained prior to PI. Follow-up information was obtained with weekly phone calls for the first 12 weeks and biweekly calls for the next 12 weeks to assess toxicity and AUA score. Removal of the stent was planned at six months after PI, or earlier due to excessive toxicity/patient request.
  
  
  RESULTS
  Median age was 66.5 years. The median prostate volume was 39 cc (range: 10-90). The median baseline AUA score was 7.5 (range: 1-21). Three patients required intermittent self-catheterization (ISC) within 3 days after PI. No patients required ISC beyond day 3 after PI. The median duration of ISC was 1 day (range: 1-2). AUA scores returned to baseline values 6 weeks after PI. The week 6 AUA score was 10 (range: 4-16). Seven patients (35%) underwent early removal because of patient preference. The reasons were: incontinence (n= 3), discomfort (n= 2), hematuria (n= 1), and obstructive symptoms (n= 1). The median time of stent removal in these patients was 13.9 weeks (range: 0.9-21.4). Thirteen patients (65%) had ISC and/or urinary catheterization post stent removal. Median time for ISC use was 10 days (range: 1-90).
  
  
  CONCLUSIONS
  Urethral stenting with Memokath®in patients undergoing PI was feasible, but resulted in relatively high rate of urinary incontinence and discomfort. Given the adverse effects experienced by patients of this study, further studies should focus only on patients with highest risk of urinary obstruction from PI or those with obstruction needing ISC.
authors.affiliation: Department of Radiation Oncology.
authors.forename: Samuel T
authors.initials: ST
authors.lastname: Chao
authors.affiliation: Department of Urology, Taussig Cancer Institute, Cleveland Clinic, USA.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Angermeier
authors.affiliation: Department of Urology, Taussig Cancer Institute, Cleveland Clinic, USA.
authors.forename: Eric A
authors.initials: EA
authors.lastname: Klein
authors.affiliation: Department of Radiation Oncology.
authors.forename: Chandana A
authors.initials: CA
authors.lastname: Reddy
authors.affiliation: Department of Urology, Taussig Cancer Institute, Cleveland Clinic, USA.
authors.forename: James C
authors.initials: JC
authors.lastname: Ulchaker
authors.affiliation: Department of Urology, Taussig Cancer Institute, Cleveland Clinic, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Stephenson
authors.affiliation: Department of Urology, Taussig Cancer Institute, Cleveland Clinic, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Campbell
authors.affiliation: Department of Radiation Oncology.
authors.forename: Jay P
authors.initials: JP
authors.lastname: Ciezki
keywords: prostate brachytherapy; prostate cancer; urethral obstruction; urethral stent